- Studies Reinforce Astellas Commitment to Overcoming Critical Shortage of New Antimicrobial Agents
MUNICH, Germany, April 02, 2007 /PRNewswire/ --Study results presented at the 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) show that the antibiotic telavancin, and the antifungal micafungin, both have the potential to meet a significant unmet need in the fight against serious hospital-acquired infections (HAIs).
Hospital-acquired, or nosocomial infections, are one of the leading causes of death and increased morbidity amongst patients in a hospital setting.(1) Estimates suggest that HAIs cost the UK economy GBP1 billion a year.(2) The greatest contributor to this cost is the increased length of hospital stay for patients with infection.(3),(4),(5)
Data presented from ATLAS 1 and ATLAS 2, two multinational phase 3 studies, show that telavancin was found to be effective for the treatment of patients with complicated skin and skin structure infections (cSSSIs), including those caused by Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA).(6),(7)
The results of the two double blind parallel studies, in which 1,867 patients were treated, showed that telavancin compared favorably to standard therapy in clinical cure, microbiological eradication, and overall therapeutic response rates. The safety profile of telavancin in these studies was compatible with treatment of patients with serious infections due to resistant bacteria.
Astellas Pharma Ltd Lovett House, Lovett Road, Staines, TW18 3AZ Tel: +44(0)1784-419615 Fax: +44(0)1784-419401 Astellas Pharma Ltd. Registered in England & Wales 0787610
Commenting on the study results, investigator Professor M
Stryjewski, Duke Clinical Research Institute, Durham, North
Carolina, USA said, "Antibio